Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR: Albuterol and Budesonide Rescue Therapy in Asthma
NCT06422689Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Primary completion
- Feb 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of salbutamol + budesonide in asthma, sponsored by AstraZeneca. Primary endpoint: Asthma exacerbation rate. Started May 2024; status: active, not recruiting.
02
Drugs
salbutamol + budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06422689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422689.